ALNY vs NKTX · P/E 76, rev $1.29B vs $188.9M cap
Alnylam Pharmaceuticals Inc (ALNY) versus Nkarta Inc (NKTX) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Nkarta Inc (NKTX) is a biotechnology company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported NKTX revenue for 2025-12-31 was $0. Net income was -$104.1M. NKTX currently screens at market cap $188.9M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. NKTX currently screens at market cap $188.9M.
Not investment advice. Open the ALNY and NKTX stock pages for the full models.
Not investment advice.